Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

BACKGROUND: This retrospective study was undertaken to determine if the plasma circulating tumor DNA (ctDNA) level and tumor biological features in patients with advanced solid tumors affected the detection of genomic alterations (GAs) by a plasma ctDNA assay. METHOD: Cell-free DNA (cfDNA) extracted...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Cathy, Yuan, Zilong, Ma, Weijie, Qi, Lihong, Mahavongtrakul, Angelique, Li, Ying, Li, Hong, Gong, Jay, Fan, Reggie R., Li, Jin, Molmen, Michael, Clark, Travis A., Pavlick, Dean, Frampton, Garrett M., Forcier, Brady, Moore, Elizabeth H., Shelton, David K., Cooke, Matthew, Ali, Siraj M., Miller, Vincent A., Gregg, Jeffrey P., Stephens, Philip J., Li, Tianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219073/
https://www.ncbi.nlm.nih.gov/pubmed/30400986
http://dx.doi.org/10.1186/s13045-018-0671-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219073/
https://www.ncbi.nlm.nih.gov/pubmed/30400986
http://dx.doi.org/10.1186/s13045-018-0671-8

Ejemplares similares